London, UK, 27 August 2008: Ark Therapeutics Group plc ("Ark" or the "Company") today announces that enrolment of patients into its Phase III pilot study for VitorTM (Study 208) has commenced. VitorTM is Ark's product to treat cachexia (involuntary muscle wasting) associated with cancer.
